The Effect of Intercostal Nerve Block With Dexamethasone and Ropivacaine on Rebound Pain After Thoracoscopic Surgery

The Effect of Intercostal Nerve Block With Dexamethasone and Ropivacaine on Rebound Pain After Thoracoscopic Surgery: a Randomized, Double-blind, Controlled Study

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05825378

Enrollment

260

Registered

2023-04-24

Start date

2023-05-01

Completion date

2025-08-06

Last updated

2023-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rebound Pain, Dexamethasone, Intercostal Nerve Block, Thoracoscopic Surgery

Brief summary

Regional nerve block is one of the commonly used methods for postoperative analgesia after thoracoscopic surgery. Recent studies have found that rebound pain may occur after regional block, which is defined as acute postoperative pain that occurs after the resolution of sensory block related to regional anesthesia, and seriously affects the quality of postoperative recovery of patients. There is evidence that rebound tenderness is associated with local anesthetic toxicity and proinflammatory effects. The aim of this study was to investigate the effect of dexamethasone on rebound pain after a single intercostal nerve block in patients undergoing thoracoscopic surgery.

Interventions

DRUGDexamethasone 8mg+0.375% ropivacaine

Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml of a mixture of 0.375% ropivacaine and 8 mg dexamethasone was injected at each point

DRUG0.375% ropivacaine

Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml 0.375% ropivacaine was injected at each point

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients scheduled for elective thoracoscopic surgery Age \> 18 years old ASA ⅰ-ⅲ Informed consent was signed

Exclusion criteria

* Patients with aoagulation disorders Patients with allergy to local anesthetics Patients with severe cardiopulmonary diseases Patients had systemic steroid use Patients with chronic pain Patients with uncontrolled diabetes and mental disorders History of drug abuse; Body Mass Index more than 35 kg.m-2 Pregnant or breastfeeding woman.

Design outcomes

Primary

Measure	Time frame	Description
The incidence of rebound pain after the disappearance of nerve block effect	8 hours after the nerve block	NRS \< 3 in PACU and NRS \> 7 after the disappearance of nerve block effect

Countries

China

Contacts

Primary ContactRuquan Han, M.D., PhD.

ruquan.han@ccmu.edu.cn8610-59976660

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026